BEACOPP regimen: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
No edit summary
Line 1: Line 1:
__NOTOC__
{{SI}}
{{SI}}
{{CMG}}; {{AE}} {{AV}}


{{SK}} Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen


==Overview==
==Overview==
'''BEACOPP''' is a [[chemotherapy regimen]] for treatment of [[Hodgkin's lymphoma]] in Stages > II. Patients typically receive treatment in cycles of 21 days with no drugs given on days 16-21. There also exists a more intensive regimen with cycles of 14 days. Usually a therapy consists of eight, sometimes six cycles. In some countries BEACOPP still is experimental, in others (eg. [[Germany]] and [[Austria]]) it is a standard therapy. The reason that the United States physicians still use ABVD (or Stanford V) is that they think that BEACOPP induces more secondary neoplasias as leukemias, etc. However, this (after 10 years of experience) is not the case. BEACOPP delivers approximately 10-15% more cures in advanced Hodgkins disease (IIB+risk factors or stages III and IV). BEACOPP is more expensive as it requires G-CSF support. However, it is well worth it because of the higher cure rates.
{{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[rituximab]], [[cyclophosphamide]], [[doxorubicin |hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride)]], [[vincristine|vincristine (Oncovin)]] and [[prednisone]] used to treat both indolent and aggressive forms of [[non-Hodgkin lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate =  | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>


==Regimen==
[[Rituximab|{{button|R – Rituximab}}]]


m² = body surface
[[Cyclophosphamide|{{button|C – Cyclophosphamide}}]]


i.v.=[[intravenous]]
[[Doxorubicin|{{button|H – Doxorubicin (Hydroxydaunomycin)}}]]


BEACOPP basic:
[[Vincristine|{{button|O – Vincristine (Oncovin)}}]]
{|
|[[Cyclophosphamide|'''(C)'''yclophosphamide]] || 650 mg/m² || (i.v.) || day 1
|-
|[[Adriamycin|'''(A)'''driamycin]] || 25 mg/m² || i.v. || day 1
|-
|[[Etoposide|'''(E)'''toposide]] || 100 mg/m² || i.v. || day 1-3
|-
|[[Vincristine|Vincristin(='''(O)'''ncovin)]] || 1,4 mg/m² (max 2 mg) || i.v. || day 8
|-
|[[Bleomycin|'''(B)'''leomycin]] || 10 mg/m² || i.v. || day 8
|-
|[[procarbazine|'''(P)'''rocarbazine]] || 100 mg/m² || orally || day 1-7
|-
|[[Prednisone|'''(P)'''rednisone]] || 40 mg/m² || orally || day 1-14
|}


[[Prednisone|{{button|P – Prednisone}}]]


BEACOPP escalated:
==Indications==
{|
* [[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma, untreated]]<ref>{{Cite journal | doi = 10.1056/NEJMoa011795 | issn = 1533-4406 | volume = 346 | issue = 4 | pages = 235–242 | last = Coiffier | first = Bertrand | coauthors = Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht | title = CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | journal = The New England Journal of Medicine | date = 2002-01-24 | pmid = 11807147 }}</ref>
|Cyclophosphamide || 1250 mg/m² KO/day || i.v. || day 1
* [[Mantle cell lymphoma]]<ref>{{Cite journal | doi = 10.1056/NEJMoa1200920 | issn = 1533-4406 | volume = 367 | issue = 6 | pages = 520–531 | last = Kluin-Nelemans | first = H. C. | coauthors = E. Hoster, O. Hermine, J. Walewski, M. Trneny, C. H. Geisler, S. Stilgenbauer, C. Thieblemont, U. Vehling-Kaiser, J. K. Doorduijn, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, P. Feugier, M. Szymczyk, M. Hallek, S. Kremers, G. Lepeu, L. Sanhes, J. M. Zijlstra, R. Bouabdallah, P. J. Lugtenburg, M. Macro, M. Pfreundschuh, V. Procházka, F. Di Raimondo, V. Ribrag, M. Uppenkamp, M. André, W. Klapper, W. Hiddemann, M. Unterhalt, M. H. Dreyling | title = Treatment of older patients with mantle-cell lymphoma | journal = The New England Journal of Medicine | date = 2012-08-09 | pmid = 22873532 }}</ref>
|-
|Adriamycin || 35 mg/m² || i.v. || day 1
|-
|Etoposide || 200 mg/m² || i.v. || day 1-3
|-
|Vincristine || 1,4 mg/m² (max 2 mg) || i.v. || day 8
|-
|Bleomycin || 10 mg/m² || i.v. || day 8
|-
|Procarbazine || 100 mg/m² || orally || day 1-7
|-
|Prednisone || 40 mg/m² || orally || day 1-14
|}


==References==
{{Reflist|2}}


==See also==
[[Category:Chemotherapy regimens]]
* [[Stanford V]]
* [[ABVD]]
 
 
 
 
 
[[Category:Cancer treatments]]
 
[[de:BEACOPP]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Revision as of 14:37, 27 February 2015

WikiDoc Resources for BEACOPP regimen

Articles

Most recent articles on BEACOPP regimen

Most cited articles on BEACOPP regimen

Review articles on BEACOPP regimen

Articles on BEACOPP regimen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on BEACOPP regimen

Images of BEACOPP regimen

Photos of BEACOPP regimen

Podcasts & MP3s on BEACOPP regimen

Videos on BEACOPP regimen

Evidence Based Medicine

Cochrane Collaboration on BEACOPP regimen

Bandolier on BEACOPP regimen

TRIP on BEACOPP regimen

Clinical Trials

Ongoing Trials on BEACOPP regimen at Clinical Trials.gov

Trial results on BEACOPP regimen

Clinical Trials on BEACOPP regimen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on BEACOPP regimen

NICE Guidance on BEACOPP regimen

NHS PRODIGY Guidance

FDA on BEACOPP regimen

CDC on BEACOPP regimen

Books

Books on BEACOPP regimen

News

BEACOPP regimen in the news

Be alerted to news on BEACOPP regimen

News trends on BEACOPP regimen

Commentary

Blogs on BEACOPP regimen

Definitions

Definitions of BEACOPP regimen

Patient Resources / Community

Patient resources on BEACOPP regimen

Discussion groups on BEACOPP regimen

Patient Handouts on BEACOPP regimen

Directions to Hospitals Treating BEACOPP regimen

Risk calculators and risk factors for BEACOPP regimen

Healthcare Provider Resources

Symptoms of BEACOPP regimen

Causes & Risk Factors for BEACOPP regimen

Diagnostic studies for BEACOPP regimen

Treatment of BEACOPP regimen

Continuing Medical Education (CME)

CME Programs on BEACOPP regimen

International

BEACOPP regimen en Espanol

BEACOPP regimen en Francais

Business

BEACOPP regimen in the Marketplace

Patents on BEACOPP regimen

Experimental / Informatics

List of terms related to BEACOPP regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen

Overview

BEACOPP regimen refers to an immunochemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.[1][2]

Regimen

R – Rituximab

C – Cyclophosphamide

H – Doxorubicin (Hydroxydaunomycin)

O – Vincristine (Oncovin)

P – Prednisone

Indications

References

  1. ↑ "NCI Thesaurus".
  2. ↑ "R-CHOP - National Cancer Institute".
  3. ↑ Coiffier, Bertrand (2002-01-24). "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma". The New England Journal of Medicine. 346 (4): 235–242. doi:10.1056/NEJMoa011795. ISSN 1533-4406. PMID 11807147. Unknown parameter |coauthors= ignored (help)
  4. ↑ Kluin-Nelemans, H. C. (2012-08-09). "Treatment of older patients with mantle-cell lymphoma". The New England Journal of Medicine. 367 (6): 520–531. doi:10.1056/NEJMoa1200920. ISSN 1533-4406. PMID 22873532. Unknown parameter |coauthors= ignored (help)
Retrieved from "https://www.wikidoc.org/index.php?title=BEACOPP_regimen&oldid=1073912"